Literature DB >> 18838521

Primary activation of antigen-specific naive CD4+ and CD8+ T cells following intranasal vaccination with recombinant bacteria.

Annalisa Ciabattini1, Elena Pettini, Peter Andersen, Gianni Pozzi, Donata Medaglini.   

Abstract

The primary activation of T-helper and T-cytotoxic cells following mucosal immunization with recombinant Streptococcus gordonii was studied in vivo by adoptive transfer of ovalbumin (OVA)-specific transgenic CD8(+) (OT-I) and CD4(+) (OT-II) T cells. A recombinant strain, expressing on the surface the vaccine antigen Ag85B-ESAT-6 from Mycobacterium tuberculosis fused to OVA T-helper and T-cytotoxic epitopes (peptides 323 to 339 and 257 to 264), was constructed and used to immunize C57BL/6 mice by the intranasal route. Recombinant, but not wild-type, bacteria induced OVA-specific CD4(+) and CD8(+) T-cell clonal expansion in cervical lymph nodes, lung, and spleen. OVA-specific CD4(+) and CD8(+) T-cell proliferation appeared first in cervical lymph nodes and later in the spleen, suggesting a possible migration of activated cells from the inductive site to the systemic district. A significant correlation between the percentages of CD4(+) and CD8(+) proliferating T cells was observed for each animal. The expression of CD69, CD44, and CD45RB on proliferating T lymphocytes changed as a function of the cell division number, confirming T-cell activation following the antigen encounter. These data indicate that intranasal immunization with recombinant S. gordonii is capable of inducing primary activation of naive antigen-specific CD4(+) and CD8(+) T cells, both locally and systemically.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18838521      PMCID: PMC2583588          DOI: 10.1128/IAI.00793-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  57 in total

1.  Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.

Authors:  A Weinrich Olsen; L A van Pinxteren; L Meng Okkels; P Birk Rasmussen; P Andersen
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Intranasal vaccination of mice against infection with Mycobacterium tuberculosis.

Authors:  G Falero-Diaz; S Challacombe; D Banerjee; G Douce; A Boyd; J Ivanyi
Journal:  Vaccine       Date:  2000-08-01       Impact factor: 3.641

Review 3.  Upper respiratory tract immunity.

Authors:  Adrian W Zuercher
Journal:  Viral Immunol       Date:  2003       Impact factor: 2.257

4.  Nasal-associated lymphoid tissue is a mucosal inductive site for virus-specific humoral and cellular immune responses.

Authors:  Adrian W Zuercher; Susan E Coffin; M Christine Thurnheer; Petra Fundova; John J Cebra
Journal:  J Immunol       Date:  2002-02-15       Impact factor: 5.422

5.  Gamma interferon-producing CD4+ T lymphocytes in the lung correlate with resistance to infection with Mycobacterium tuberculosis.

Authors:  A A Chackerian; T V Perera; S M Behar
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

6.  Immunization with recombinant Streptococcus gordonii expressing tetanus toxin fragment C confers protection from lethal challenge in mice.

Authors:  D Medaglini; A Ciabattini; M R Spinosa; T Maggi; H Marcotte; M R Oggioni; G Pozzi
Journal:  Vaccine       Date:  2001-02-28       Impact factor: 3.641

7.  Comparative evaluation of intranasal and subcutaneous route of immunization for development of mucosal vaccine against experimental tuberculosis.

Authors:  Pramod K Giri; Suraj B Sable; Indu Verma; Gopal K Khuller
Journal:  FEMS Immunol Med Microbiol       Date:  2005-03-18

8.  Immunogenicity of the B monomer of Escherichia coli heat-labile toxin expressed on the surface of Streptococcus gordonii.

Authors:  S Ricci; D Medaglini; C M Rush; A Marcello; S Peppoloni; R Manganelli; G Palú; G Pozzi
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

9.  Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis.

Authors:  T Mark Doherty; Anja Weinrich Olsen; Laurens van Pinxteren; Peter Andersen
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

10.  Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN-gamma in their lungs.

Authors:  I V Lyadova; H M Vordermeier; E B Eruslanov; S V Khaidukov; A S Apt; R G Hewinson
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

View more
  18 in total

Review 1.  Non-invasive administration of biodegradable nano-carrier vaccines.

Authors:  Mohd Abul Kalam; Abdul Arif Khan; Aws Alshamsan
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

Review 2.  Recent trends and advances in microbe-based drug delivery systems.

Authors:  Pravin Shende; Vasavi Basarkar
Journal:  Daru       Date:  2019-08-02       Impact factor: 3.117

3.  Pulmonary mucosal immunity mediated through CpG provides adequate protection against pulmonary Mycobacterium tuberculosis infection in the mouse model. A role for type I interferon.

Authors:  Amber Troy; Sandra C Esparza-Gonzalez; Alicia Bartek; Elizabeth Creissen; Linda Izzo; Angelo A Izzo
Journal:  Tuberculosis (Edinb)       Date:  2020-06-06       Impact factor: 3.131

4.  Immunity in the spleen and blood of mice immunized with irradiated Toxoplasma gondii tachyzoites.

Authors:  Nahiara Esteves Zorgi; Andrés Jimenez Galisteo; Maria Notomi Sato; Nanci do Nascimento; Heitor Franco de Andrade
Journal:  Med Microbiol Immunol       Date:  2016-01-05       Impact factor: 3.402

5.  Distribution of primed T cells and antigen-loaded antigen presenting cells following intranasal immunization in mice.

Authors:  Annalisa Ciabattini; Elena Pettini; Fabio Fiorino; Gennaro Prota; Gianni Pozzi; Donata Medaglini
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

6.  Cellular immune responses to nine Mycobacterium tuberculosis vaccine candidates following intranasal vaccination.

Authors:  Suraj B Sable; Mani Cheruvu; Subhadra Nandakumar; Sunita Sharma; Kakali Bandyopadhyay; Kathryn L Kellar; James E Posey; Bonnie B Plikaytis; Rama Rao Amara; Thomas M Shinnick
Journal:  PLoS One       Date:  2011-07-25       Impact factor: 3.240

7.  Characterization of the Antigen-Specific CD4(+) T Cell Response Induced by Prime-Boost Strategies with CAF01 and CpG Adjuvants Administered by the Intranasal and Subcutaneous Routes.

Authors:  Annalisa Ciabattini; Gennaro Prota; Dennis Christensen; Peter Andersen; Gianni Pozzi; Donata Medaglini
Journal:  Front Immunol       Date:  2015-08-28       Impact factor: 7.561

8.  Prime-boost strategies in mucosal immunization affect local IgA production and the type of th response.

Authors:  Fabio Fiorino; Elena Pettini; Gianni Pozzi; Donata Medaglini; Annalisa Ciabattini
Journal:  Front Immunol       Date:  2013-05-29       Impact factor: 7.561

9.  A Stochastic Model for CD4+ T Cell Proliferation and Dissemination Network in Primary Immune Response.

Authors:  Alessandro Boianelli; Elena Pettini; Gennaro Prota; Donata Medaglini; Antonio Vicino
Journal:  PLoS One       Date:  2015-08-24       Impact factor: 3.240

10.  The role of host and microbial factors in the pathogenesis of pneumococcal bacteraemia arising from a single bacterial cell bottleneck.

Authors:  Alice Gerlini; Leonarda Colomba; Leonardo Furi; Tiziana Braccini; Ana Sousa Manso; Andrea Pammolli; Bo Wang; Antonio Vivi; Maria Tassini; Nico van Rooijen; Gianni Pozzi; Susanna Ricci; Peter W Andrew; Uwe Koedel; E Richard Moxon; Marco R Oggioni
Journal:  PLoS Pathog       Date:  2014-03-20       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.